PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jexpmedHomeThe Rockefeller University PressThis articleEditorsContactInstructions for AuthorsThis issue
 
J Exp Med. Apr 17, 2006; 203(4): 809–812.
PMCID: PMC2118289
Commentary
Helper T cell differentiation enters a new era: Le Roi est mort; vive le Roi!
Cristina M. Tato, Arian Laurence, and John J. O'Shea
C.M.T., A.L., and J.J.O. are at Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892.
CORRESPONDENCE C.M.T: tatoc/at/mail.nih.gov
Abstract
In the dark ages of T cell biology, we considered two fates for differentiated CD4+ T cells: T helper (Th)1 and Th2 cells. Now we know that the reality is much more complex and interesting. The newest Th cell subset produces the cytokine IL-17. New evidence shows that the IL-17–related cytokine IL-25 is essential for Th2 responses in two infectious disease models.
In this commentary, we will consider the new information pertaining to IL-25 in the context of the emerging understanding of the regulation and action of other IL-17 family members. We will also discuss how these new insights change our concept of Th cell differentiation and immunoregulation in host defense and immune-mediated disease.
The Th1/Th2 cell dichotomy and the essential role of the cytokine environment in driving their differentiation are well accepted. Interleukin (IL)-12, acting via the transcription factors Stat4 and T-bet, drives the differentiation of naive CD4+ T cells into interferon (IFN)- γ–producing Th1 cells, whereas IL-4, acting via Stat6 and GATA3, drives the differentiation of IL-4–producing Th2 cells. Numerous infectious models support the notion that Th1 and Th2 cells act independently. Th1 cells are responsible for the cell-mediated elimination of intracellular pathogens, whereas eradication of helminthic infestations is dependent on adequate Th2 responses. However, the immunopathogenesis of autoimmune disease does not fit quite so neatly into this dichotomy. CD4+ T cells can also differentiate into cells that produce the immunosuppressive cytokines IL-10 and TGFβ, so-called Th3 cells, and can become “adaptive” regulatory T cells. Both cell types appear to protect against autoimmunity. Studies of experimental autoimmune encephalophalomyelitis and adjuvant-induced arthritis have pointed to the importance of yet another Th cell subset, which produces IL-17 and is now termed Th17 cells. Although this population of T cells has been implicated in the exacerbation of autoimmune pathology (13), the role of Th17 cells in host defense remains to be elucidated.
The subject of two papers in the issue (Owyang et al., p. 843 [4] and Fallon et al., p. 1105 [5]) is the Th2-like cytokine, IL-25, which as a member of the IL-17 family is also known as IL-17E. Structurally, this family of six cytokines (IL-17A-F) is thought to form cystine knots and in this respect is related to other better known cytokines such as TGFβ and platelet-derived growth factor. IL-17 (IL-17A) was originally reported to be produced mainly by effector and memory CD4+ T cell subsets, but has more recently been suggested to be more widely expressed (6, 7). IL-17F is located adjacent to IL-17 on mouse chromosome 1 (human chromosome 6), and although it seems to be regulated in a similar manner, it may be more widely expressed than IL-17. Less well studied are IL-17B, IL-17C, and IL-17D, which are thought to be expressed in a variety of nonhematopoeitic tissues, although IL-17D is reported to be produced by CD4+ T cells (8). Five IL-17 receptors have been identified, but only the receptors for IL-17/IL-17F and IL-25 have been characterized. The IL-17 receptor is structurally distinct from other cytokine receptors, and engagement of the receptor activates MAP kinases and NF-κB. Signaling via IL-25 is reported to be dependent on the adaptor molecule TRAF6 (9).
With respect to their biological actions, IL-17 and IL-17F are most intensively studied. These cytokines evoke inflammation largely by inducing the production of chemokines, as well as granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor, with the subsequent recruitment of polymorphonuclear leukocytes. In some settings, however, IL-17– or IL-17F–induced inflammation is dominated by macrophages (10). The induction of matrix metalloproteinase production by epithelial cells may be another important proinflammatory function of IL-17 (11). Abundant data point to pathogenic roles of IL-17 in models of immune-mediated disease and in human autoimmune disorders. Less well defined are the beneficial roles of IL-17 family cytokines in host defense, although recent data indicate IL-17 is important for resistance against Klebsiella pneumoniae and Mycobacterium tuberculosis (1214).
Unlike IL-17 and IL-17F, IL-25 is produced by Th2 cells and mast cells (15). Administration of recombinant IL-25 (rIL-25) to mice has been shown to evoke an inflammatory response characterized by the overproduction of Th2 cytokines, hyperproduction of immunoglobulins IgA and IgE, overproduction of mucus, epithelial cell hyperplasia, and eosinophilia. Furthermore, the observed pathology was dependent on the classical Th2 cytokines IL-4 and IL-13, as shown by the lack of effect of administering rIL-25 to mice that lack these cytokines or their cognate receptor.
Th17 cells are now thought to be a separate lineage of effector Th cells, but the optimal recipe to differentiate Th17 cells in vitro remains somewhat unclear (10, 1618), and the in vivo requirements for their differentiation have yet to be firmly established. Several groups have pointed to the importance of IL-23 as a critical ingredient for the generation and/or maintenance of this lineage (10, 13, 1720). It should be kept in mind that because of its structural similarity to IL-12 (p35/p40) (2124) IL-23 (p19/p40) also has the potential to induce a Th1-like response. Recently, another group has come up with a different recipe to make Th17 cells that involves a milieu of cytokines produced by lipopolysaccharide-activated dendritic cells (namely IL-1, IL-6, and TNF-α) and the presence of TGFβ (25). These findings not only illustrate that there is overlap in the groups of cytokines that induce different populations of CD4+ T cells, but also emphasize that a particular cytokine, in this case TGFβ, may have both proinflammatory (Th17-inducing) and antiinflammatory (Th3-inducing) roles, depending on the circumstances.
In this issue, two new studies by Owyang et al. (4) and Fallon et al. (5) show that IL-25/ mice have increased susceptibility to the parasitic helminthes, Trichuris muris, and Nippostrongylus brasiliensis. Both groups found that the antihelminth activity of IL-25 depends on its ability to induce the Th2-associated cytokines IL-4, IL-5, and IL-13. In the case of T. muris infection, the susceptibility of IL-25−/− mice was associated with impaired IL-4 and IL-13 production and reduced Trichuris-specific IgG1 and total IgE. In addition, chronically infected IL-25/ mice had exacerbated pathology, which was characterized by severe inflammation and disruption of intestinal epithelial structure, and was associated with increased production of IFN-γ, IL-17, and total IgG2a. Thus, in addition to an essential role in driving antihelminth Th2 responses, this study implies an antiinflammatory role for IL-25 in suppressing Th1 and Th17 responses. In contrast, Fallon et al. (5) found that IL-25 was not absolutely required for the generation of Th2 responses in N. brasiliensis infection, but that IL-25 was important for the timely resolution of the infection. When IL-25−/− mice were challenged with N. brasiliensis, the polarization of the Th2 response, manifested as enhanced IL-4, IL-5, and IL-13 production, was delayed. This resulted in slower elimination of worms and delayed IgE production. Interestingly, blockade of Th1 responses with anti–IL-12 and anti–IFN-γ antibodies reduced the worm burden and enhanced Th2 responses in Trichuris-infected IL-25−/− mice, as well as in the naturally susceptible AKR mouse strain. Thus, IL-25 does not appear to be absolutely essential for Th2 responses to some helminthes, and may promote host defense by inhibiting expression of type 1 cytokines.
Which cell types produce IL-25 and which cell types respond to it? Using mice that have the reporter lacZ knocked into the IL-25 locus, Owyang et al. (4) found that IL-25 expression is, in fact, very limited. It was constitutively expressed by CD4+ and CD8+ T cells in the gut but was not expressed in a variety of innate immune cells. These data hint at the possible existence of effector T cells that selectively produce IL-25 (a putative Th25 lineage), which may play a specific role in mucosal immunity. In their study, Fallon et al. (5) report that the target of IL-25 is a nonlymphoid c-kit+ cell present in the draining lymph node. The finding that the IL-25–mediated expulsion of N. brasiliensis was T and B cell independent emphasizes the importance of this nonlymphoid population. Using mice in which the reporter eGFP was knocked into the IL-4 locus, Fallon et al. (5) show that nonlymphoid c-kit+ cells are major producers of IL-4 during infection and their appearance in the draining lymph node precedes the expansion of IL-4–producing CD4+ cells. These findings are consistent with previous work using rIL-25, which indicated that this cytokine does not have direct effects on differentiating T cells, but rather that its action requires nonlymphoid cells.
As all good studies should, these two papers raise more questions than they answer (4, 5). Together they suggest a new conceptual framework for Th2 cell differentiation. The findings are of considerable interest because, compared to the seemingly clear cut mechanisms involved in Th1 cell differentiation, the factors that drive Th2 cell differentiation have been more difficult to understand. Both groups convincingly show that IL-25 is an important regulator of Th2 responses and host defense. Whether IL-25 is produced by T cells for T cells or by APCs for nonlymphoid effector populations it indisputably serves to enhance IL-4 production resulting in amplification of Th2-mediated immunity. These reports also indicate that IL-25 controls inflammation during helminth infection and dampens counterproductive Th1 responses, independent of IL-25's effects on Th2 cell differentiation. The duality of IL-25 activity mirrors that of the well-known immunosuppressive cytokine TGFβ, which, as mentioned, induces the polarization of proinflammatory Th17 cells (25).
The paradigm of Th1 and Th2 responses is firmly supported by an immense amount of in vitro data but, more importantly, is substantiated in many infectious disease models and some autoimmune disease models. As the papers in this issue exemplify (4, 5), the generation of other T cell subsets in models of host defense is less clear cut (Fig. 1). IFN-γ promotes Th1 cell differentiation by inducing T-bet, but inhibits both Th17 cell and Th2 cell differentiation (26, 27). Similarly, IL-4, by inducing GATA-3, inhibits Th17 cell and Th1 cell differentiation. Thus, it would appear that the generation of Th1, Th2, and Th17 cells is carefully balanced. In contrast to the well-described positive effects of IFN-γ and IL-4 on their respective lineages, no data have been provided indicating that IL-17 directly regulates Th cell differentiation, either positively or negatively (27, 28). Furthermore, will we find that like Th1 and Th17 cells, IL-25–secreting cells are really a distinct lineage from Th2 cells and subject to different modes of regulation? To this end, the question of whether the putative Th25 cell population expresses lineage-specific transcription factors that determine its cytokine production profile will likely be a focus of future studies. Further studies are also needed to understand and define the functional role of Th17 and Th25 cells as either primary effectors similar to Th1 and Th2 cells, or sentinel populations that promote or enhance more specific cell-mediated immunity in mucosal tissues. One might envision a scenario in which pleiotropic cytokines such as IL-17, TGFβ, and IL-25 not only potentiate early Th responses and recruitment of cells to lymph nodes and tissues, but also regulate aberrant inflammatory responses during the resolution of infection. The ability of IL-25 to limit Th1-induced inflammation might be an example of the latter. How all of this relates to human health and disease is less clear, and with future studies refined concepts of T cell differentiation will come to bear.
Figure 1.
Figure 1.
Th cell differentiation: how many flavors? On pathogen challenge, CD4+ T cells will differentiate into either IFN-γ–producing Th1 cells or IL-4–producing Th2 effector cells, which directly cross-regulate each other. Th17 (more ...)
In conclusion, this is a very exciting time for T cell biologists. In the age of monarchies, the expression “Le roi est mort; vive le roi” marked the passing of eras, ushering out one regime while introducing another. Analogously, it might be said, “T cell differentiation is dead; long live T cell differentiation.” Suddenly, understanding the molecular regulation of T cell differentiation has become much more complicated. The simple notion of a dualistic view of Th1/Th2 cell differentiation is moribund, but the era of new complexities of immunoregulation promises to provide better understanding of mechanisms of host defense and immune-mediated disease.
Acknowledgments
The authors thank Richard Siegel, Zhi Chen, and Wendy Watford for helpful discussions.
1. Chabaud, M., J.M. Durand, N. Buchs, F. Fossiez, G. Page, L. Frappart, and P. Miossec. 1999. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42:963–970. [PubMed]
2. Zhang, G.X., B. Gran, S. Yu, J. Li, I. Siglienti, X. Chen, M. Kamoun, and A. Rostami. 2003. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J. Immunol. 170:2153–2160. [PubMed]
3. Langrish, C.L., Y. Chen, W.M. Blumenschein, J. Mattson, B. Basham, J.D. Sedgwick, T. McClanahan, R.A. Kastelein, and D.J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201:233–240. [PMC free article] [PubMed]
4. Owyang, A.M., C. Zaph, E.H. Willson, K.J. Guild, T. McClanahan, H.R.P. Miller, D.J. Cua, M. Goldschmidt, C.A. Hunter, R.A. Kastelein, and D. Artis. 2006. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J. Exp. Med. 203:843–849. [PMC free article] [PubMed]
5. Fallon, P.G., S.J. Ballantyne, N.E. Mangan, J.L. Barlow, A. Dasvarma, D.R. Hewett, A. McIlgorm, H.E. Jolin, and A.N.J. McKenzie. 2006. Identification of an interleukin (IL)-25–dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J. Exp. Med. 203:1105–1116. [PMC free article] [PubMed]
6. Kawaguchi, M., M. Adachi, N. Oda, F. Kokubu, and S.K. Huang. 2004. IL-17 cytokine family. J. Allergy Clin. Immunol. 114:1265–1273. [PubMed]
7. Kolls, J.K., and A. Linden. 2004. Interleukin-17 family members and inflammation. Immunity. 21:467–476. [PubMed]
8. Starnes, T., H.E. Broxmeyer, M.J. Robertson, and R. Hromas. 2002. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J. Immunol. 169:642–646. [PubMed]
9. Maezawa, Y., H. Nakajima, K. Suzuki, T. Tamachi, K. Ikeda, J. Inoue, Y. Saito, and I. Iwamoto. 2006. Involvement of TNF receptor-associated factor 6 in IL-25 receptor signaling. J. Immunol. 176:1013–1018. [PubMed]
10. Park, H., Z. Li, X.O. Yang, S.H. Chang, R. Nurieva, Y.H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133–1141. [PMC free article] [PubMed]
11. Jovanovic, D.V., J. Martel-Pelletier, J.A. Di Battista, F. Mineau, F.C. Jolicoeur, M. Benderdour, and J.P. Pelletier. 2000. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin- 17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum. 43:1134–1144. [PubMed]
12. Happel, K.I., P.J. Dubin, M. Zheng, N. Ghilardi, C. Lockhart, L.J. Quinton, A.R. Odden, J.E. Shellito, G.J. Bagby, S. Nelson, and J.K. Kolls. 2005. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med. 202:761–769.
13. Happel, K.I., M. Zheng, E. Young, L.J. Quinton, E. Lockhart, A.J. Ramsay, J.E. Shellito, J.R. Schurr, G.J. Bagby, S. Nelson, and J.K. Kolls. 2003. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J. Immunol. 170:4432–4436. [PMC free article] [PubMed]
14. Happel, K.I., E.A. Lockhart, C.M. Mason, E. Porretta, E. Keoshkerian, A.R. Odden, S. Nelson, and A.J. Ramsay. 2005. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect. Immun. 73:5782–5788. [PMC free article] [PubMed]
15. Fort, M.M., J. Cheung, D. Yen, J. Li, S.M. Zurawski, S. Lo, S. Menon, T. Clifford, B. Hunte, R. Lesley, et al. 2001. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 15:985–995. [PubMed]
16. Aarvak, T., M. Chabaud, P. Miossec, and J.B. Natvig. 1999. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J. Immunol. 162:1246–1251. [PubMed]
17. Aggarwal, S., N. Ghilardi, M.H. Xie, F.J. de Sauvage, and A.L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910–1914. [PubMed]
18. Harrington, L.E., R.D. Hatton, P.R. Mangan, H. Turner, T.L. Murphy, K.M. Murphy, and C.T. Weaver. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123–1132. [PubMed]
19. Ghilardi, N., N. Kljavin, Q. Chen, S. Lucas, A.L. Gurney, and F.J. De Sauvage. 2004. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J. Immunol. 172:2827–2833. [PubMed]
20. Khader, S.A., J.E. Pearl, K. Sakamoto, L. Gilmartin, G.K. Bell, D.M. Jelley-Gibbs, N. Ghilardi, F. deSauvage, and A.M. Cooper. 2005. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J. Immunol. 175:788–795. [PubMed]
21. Hunter, C.A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5:521–531. [PubMed]
22. Watford, W.T., B.D. Hissong, J.H. Bream, Y. Kanno, L. Muul, and J.J. O'Shea. 2004. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT 4. Immunol. Rev. 202:139–156. [PubMed]
23. Watford, W.T., and J.J. O'Shea. 2003. Autoimmunity: A case of mistaken identity. Nature. 421:706–708. [PubMed]
24. Trinchieri, G., S. Pflanz, and R.A. Kastelein. 2003. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 19:641–644. [PubMed]
25. Veldhoen, M., R.J. Hocking, C.J. Atkins, R.M. Locksley, and B. Stockinger. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179–189. [PubMed]
26. Agnello, D., C.S. Lankford, J. Bream, A. Morinobu, M. Gadina, J.J. O'Shea, and D.M. Frucht. 2003. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J. Clin. Immunol. 23:147–161. [PubMed]
27. Rao, A., and O. Avni. 2000. Molecular aspects of T-cell differentiation. Br. Med. Bull. 56:969–984. [PubMed]
28. Lighvani, A.A., D.M. Frucht, D. Jankovic, H. Yamane, J. Aliberti, B.D. Hissong, B.V. Nguyen, M. Gadina, A. Sher, W.E. Paul, and J.J. O'Shea. 2001. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. USA. 98:15137–15142. [PubMed]
Articles from The Journal of Experimental Medicine are provided here courtesy of
The Rockefeller University Press